---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-001350"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T10:54:20.432469+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quoin reports Netherton Syndrome patient achieves near-clear skin after 12 weeks of QRX003 twice-daily

## Summary
- M-IASI score improved from 18 to 3; WINRS from 7 to 2; IGA from Moderate to Almost Clear after 12 weeks.
- Patient satisfaction scores further improved from 6-week to 12-week mark; no safety concerns observed.
- Data follows positive interim results announced Dec 2024; first subject completed full 12-week twice-daily dosing with QRX003.
- Quoin is developing QRX003 for Netherton Syndrome, a rare genetic skin disorder with no approved therapies.

## SEC filing metadata
- accession: 0001104659-25-001350
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925001350/0001104659-25-001350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925001350/tm252105d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-001350
- JSON: https://secwatch.observer/filing/0001104659-25-001350.json
- Plain text: https://secwatch.observer/filing/0001104659-25-001350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.